CD147/EMMPRIN and CD44 are potential therapeutic targets for metastatic prostate cancer

Current Cancer Drug Targets

Volumn 10, Issue 3, 2010, Pages 287-306

  Hao, J L ^a,b   Cozzi, P J ^a,b   Khatri, A ^b,c   Power, C A ^b,c   Li, Y ^a,b  

^a ST GEORGE HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

Cancer therapy; CD147; CD44; Metastasis; Multidrug resistance; Prostate cancer

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; BIVATUZUMAB MERTANSINE; BIVATUZUMAB RE 186; CD147 ANTIGEN; CELL MARKER; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; DOXORUBICIN DERIVATIVE; DOXORUBICIN HYALURONIC ACID BIOCONJUGATE; HERMES ANTIGEN; HYALURONIC ACID DERIVATIVE; IODINE 131; IRINOTECAN; IRINOTECAN HYALURONIC ACID BIOCONJUGATE; LICARTIN; METUXIMAB I 131; MONOCARBOXYLATE TRANSPORTER; MONOCLONAL ANTIBODY; PACLITAXEL DERIVATIVE; PACLITAXEL HYALURONIC ACID BIOCONJUGATE; RHENIUM 186; UNCLASSIFIED DRUG;

ARTICLE; BLADDER CANCER; BLOOD TOXICITY; BONE MARROW TOXICITY; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER STEM CELL; CELL DIFFERENTIATION; COLORECTAL CANCER; DRUG TARGETING; EARLY CANCER; ESOPHAGUS CARCINOMA; HEAD AND NECK CARCINOMA; HUMAN; LIPOSOMAL GENE DELIVERY SYSTEM; LIVER CANCER; METASTASIS; MULTIDRUG RESISTANCE; NONHUMAN; OVARY CANCER; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RNA INTERFERENCE; SKIN TOXICITY;

ANIMALS; ANTIGENS, CD147; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; CELL ADHESION; CELL MOVEMENT; DRUG RESISTANCE, NEOPLASM; GENE THERAPY; HUMANS; HYALURONIC ACID; IMMUNOTHERAPY; MALE; MONOCARBOXYLIC ACID TRANSPORTERS; NEOPLASM INVASIVENESS; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77952797816     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800910791190193     Document Type: Article

References (216)

1. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Thun, M. J. Cancer statistics, 2009. CA Cancer J. Clin. 2009, 59, 225-249.
2. Hull, G. W.; Rabbani, F.; Abbas, F.; Wheeler, T. M.; Kattan, M. W.; Scardino, P. T. Cancer control with radical prostatectomy alone in 1000 consecutive patients. J. Urol. 2002, 167, 528-534.
3. Roehl, K. A.; Han, M.; Ramos, C. G.; Antenor, J. A.; Catalona, W. J. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3478 consecutive patients: longterm results. J. Urol. 2004, 172, 910-914.
4. Chang, S. S.; Kibel, A. S. The role of systemic cytotoxic therapy for prostate cancer. BJU Int. 2009, 103, 8-17.
5. Valdespino, V.; Tsagozis, P.; Pisa, P. Current perspectives in the treatment of advanced prostate cancer. Med. Oncol. 2007, 24, 273-286.
6. Bubendorf, L.; Schopfer, A.; Wagner, U.; Sauter, G.; Moch, H.; Willi, N.; Gasser, T. C.; Mihatsch, M. J. Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients. Hum. Pathol. 2000, 31, 578-583.
7. Verhagen, P. Predicting the future in castration-resistant prostate cancer. Lancet Oncol. 2009, 10, 201-202.
8. Rau, K. M.; Kang, H. Y.; Cha, T. L.; Miller, S. A.; Hung, M. C. The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers. Endocr. Relat. Cancer 2005, 12, 511-532.
9. Berry, W.; Eisenberger, M. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy. Oncologist 2005, 10, 30-39.
10. Clarke, N. W. Management of the spectrum of hormone refractory prostate cancer. Eur. Urol. 2006, 50, 428-438.
11. Petrylak, D. P.; Tangen, C. M.; Hussain, M. H.; Lara, Jr. P. N.; Jones, J. A.; Taplin, M. E.; Burch, P. A.; Berry, D.; Moinpour, C.; Kohli, M.; Benson, M. C.; Small, E. J.; Raghavan, D.; Crawford, E. D. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 2004, 351, 1513-1520.
12. Tannock, I. F.; de Wit, R.; Berry, W. R.; Horti, J.; Pluzanska, A.; Chi, K. N.; Oudard, S.; Theodore, C.; James, N. D.; Turesson, I.; Rosenthal, M. A.; Eisenberger, M. A. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004, 351, 1502-1512.
13. Petrylak, D. P. Future directions in the treatment of androgenindependent prostate cancer. Urology 2005, 65, 8-12.
14. Calabro, F.; Sternberg, C. N. Current indications for chemotherapy in prostate cancer patients. Eur. Urol. 2007, 51, 17-26.
15. Chung, L. W.; Huang, W. C.; Sung, S. Y.; Wu, D.; Odero-Marah, V.; Nomura, T.; Shigemura, K.; Miyagi, T.; Seo, S.; Shi, C.; Molitierno, J.; Elmore, J.; Anderson, C.; Isotani, S.; Edlund, M.; Hsieh, C. L.; Wang, R.; Shehata, B.; Zhau, H. E. Stromal-epithelial interaction in prostate cancer progression. Clin. Genitourin. Cancer 2006, 5, 162-170.
16. Mimeault, M.; Pommery, N.; Henichart, J. P. New advances on prostate carcinogenesis and therapies: involvement of EGF-EGFR transduction system. Growth Factors 2003, 21, 1-14.
17. Hernes, E.; Fossa, S. D.; Berner, A.; Otnes, B.; Nesland, J. M. Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence. Br. J. Cancer 2004, 90, 449-454.
18. Bartlett, J. M.; Brawley, D.; Grigor, K.; Munro, A. F.; Dunne, B.; Edwards, J. Type I receptor tyrosine kinases are associated with hormone escape in prostate cancer. J. Pathol. 2005, 205, 522-529.
19. Mimeault, M.; Batra, S. K. Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis 2006, 27, 1-22.
20. Mimeault, M.; Moore, E.; Moniaux, N.; Henichart, J. P.; Depreux, P.; Lin, F. F.; Batra, S. Cytotoxic effects induced by a combination of cyclopamine and gefitinib, the selective hedgehog and epidermal growth factor receptor signaling inhibitors, in prostate cancer cells. Int. J. Cancer 2006, 118, 1022-1031.
21. Miletti-González, K. E.; Chen, S.; Muthukumaran, N.; Saglimbeni, G. N.; Wu, X.; Yang, J.; Apolito, K.; Shih, W. J.; Hait, W. N.; Rodríguez-Rodríguez, L. The CD44 receptor interacts with P- Glycoprotein to promote cell migration and invasion in cancer. Cancer Res. 2005, 65, 6660-6667.
22. Misra, S.; Ghatak, S.; Zoltan-Jones, A.; Toole, B. P. Regulation of multidrug resistance in cancer cells by hyaluronan. J. Biol. Chem. 2003, 278, 25285-25288.
23. Ohashi, R.; Takahashi, F.; Cui, R.; Yoshioka, M.; Gu, T.; Sasaki, S.; Tominag, S., Nishio, K., Tanabe, K. K., Takahashi, K. Interaction between CD44 and hyaluronate induces chemoresistance in non-small cell lung cancer cell. Cancer Lett. 2007, 252, 225-234.
24. Omara-Opyene, A. L.; Qiu, J.; Shah, G. V.; Iczkowski, K. A. Prostate Cancer Invasion Is Influenced More by Expression of a CD44 Isoform Including Variant 9 Than by MUC18. Lab. Invest. 2004, 84, 894-907.
25. Gao, A. C.; Lou, W.; Sleeman, J. P.; Isaacs, J. T. Metastasis suppression by the standard CD44 isoform does not require the binding of prostate cancer cells to hyaluronate. Cancer Res. 1998, 58, 2350-2352.
26. Madigan, M. C.; Kingsley, E. A.; Cozzi, P. J.; Delprado, W. J.; Russell, P. J.; Li, Y. The Role of Extracellular Matrix Metalloproteinase Inducer Protein in Prostate Cancer Progression. Cancer Immunol. Immunother. 2008, 57, 1367-1379.
27. Biswas, C.; Zhang, Y.; DeCastro, R.; Guo, H.; Nakamura, T.; Kataoka, H.; Nabeshima, K. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res. 1995, 55, 434-439.
28. Tang, W.; Chang, S. B.; Hemler, M. E. Links between CD147 Function, Glycosylation, and Caveolin-1. Mol. Biol. Cell. 2004, 15, 4043-4050.
29. Miyauchi, T.; Masuzawa, Y.; Muramatsu, T. The basigin group of the immunoglobulin superfamily: complete conservation of a segment in and around transmembrane domains of human and mouse basigin and chicken HT7 antigen. J. Biochem. 1991, 110, 770-774.
30. Muramatsu, T.; Miyauchi T. Basigin (CD147): a multifunctional transmembrane protein involved in reproduction, neural function, inflammation and tumor invasion. Histol. Histopathol. 2003, 18, 981-987.
31. Guo, H.; Majmudar, G.; Jensen, T. C.; Biswas, C.; Toole, B. P.; Gordon, M. K. Characterization of the gene for human EMMPRIN, a tumor cell surface inducer of matrix metalloproteinases. Gene 1998, 220, 99-108.
32. Sun, J.; Hemler, M. E. Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer Res. 2001, 61, 2276-2281.
33. Yoshida, S.; Shibata, M.; Yamamoto, S.; Hagihara, M.; Asai, N.; Takahashi, M.; Mizutani, S.; Muramatsu, T.; Kadomatsu, K. Homo-oligomer formation by basigin, an immunoglobulin superfamily member, via its N-terminal immunoglobulin domain. Eur. J. Biochem. 2000, 267, 4372-4380.
34. Nabeshima, K.; Suzumiya, J.; Nagano, M.; Ohshima, K.; Toole, B. P.; Tamura, K.; Iwasaki, H.; Kikuchi, M. EMMPRIN, a Cell Surface Inducer of Matrix Metalloproteinases (MMPs), Is Expressed in T-Cell Lymphomas. J. Pathol. 2004, 202, 341-351.
35. Tang, W.; Hemler M. E. Caveolin-1 regulates matrix metalloproteinases-1 induction and CD147/EMMPRIN cell surface clustering. J. Biol. Chem. 2004, 279, 11112-11118.
36. Nabeshima, K.; Iwasaki, H.; Koga, K.; Hojo, H.; Suzumiya, J.; Kikuchi, M. EMMPRIN (Basigin/CD147): Matrix Metalloproteinase Modulator and Multifunctional Cell Recognition Molecule That Plays a Critical Role in Cancer Progression. Pathol. Int. 2006, 56, 359-367.
37. Kirk, P.; Wilson, M. C.; Heddle, C.; Brown, M. H.; Barclay, A. N.; Halestrap, A. P. CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression. EMBO J. 2000, 19, 3896-3904.
38. Pushkarsky, T.; Zybarth, G.; Dubrovsky, L.; Yurchenko, V.; Tang, H.; Guo, H.; Toole, B.; Sherry, B.; Bukrinsky, M. CD147 facilitates HIV-1 infection by interacting with virus-associated cyclophilin A. Proc. Natl. Acad. Sci. USA 2001, 98, 6360-6365.
39. Yurchenko, V.; O'Connor, M.; Dai, W. W.; Guo, H.; Toole, B.; Sherry, B.; Bukrinsky, M. CD147 is a signaling receptor for cyclophilin B. Biochem. Biophys. Res. Commun. 2001, 288, 786-788.
40. Pushkarsky, T.; Yurchenko, V.; Vanpouille, C.; Brichacek, B.; Vaisman, I.; Hatakeyama, S.; Nakayama, K. I.; Sherry, B.; Bukrinsky, M. I. Cell surface expression of CD147/EMMPRIN is regulated by cyclophilin 60. J. Biol. Chem. 2005, 280, 27866-27871.
41. Tang, Y.; Nakada, M. T.; Kesavan, P.; McCabe, F.; Millar, H.; Rafferty, P.; Bugelski, P.; Yan, L. Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res. 2005, 65, 3193-3199.
42. Kaname, T.; Miyauchi, T.; Kuwano, A.; Matsuda, Y.; Muramatsu, T.; Kajii, T. Mapping basigin (BSG), a member of the immunoglobulin superfamily, to 19p13.3. Cytogenet. Cell Genet. 1993, 64, 195-197.
43. Fadool J. M.; Linser P. J. 5A11 antigen is a cell recognition molecule which is involved in neuronal-glial interactions in avian neural retina. Dev. Dyn. 1993, 196, 252-262.
44. Igakura, T.; Kadomatsu, K.; Kaname, T.; Muramatsu, H.; Fan, Q. W.; Miyauchi, T.; Toyama, Y.; Kuno, N.; Yuasa, S.; Takahashi, M.; Senda, T.; Taguchi, O.; Yamamura, K.; Arimura, K.; Muramatsu, T. A null mutation in basigin, an immunoglobulin superfamily member, indicates its important roles in peri-implantation development and spermatogenesis. Dev. Biol. 1998, 194, 152-165.
45. Hori, K.; Katayama, N.; Kachi, S.; Kondo, M.; Kadomatsu, K.; Usukura, J.; Muramatsu, T.; Mori, S.; Miyake, Y. Retinal dysfunction in basigin deficiency. Invest. Ophthalmol. Vis. Sci. 2000, 41, 3128-3133.
46. Igakura, T.; Kadomatsu, K.; Taguchi, O.; Muramatsu, H.; Kaname, T.; Miyauchi, T.; Yamamura, K.; Arimura, K.; Muramatsu, T. Roles of basigin, a member of the immunoglobulin superfamily, in behavior as to an irritating odor, lymphocyte response, and bloodbrain barrier. Biochem. Biophys. Res. Commun. 1996, 224, 33-36.
47. Carmeliet, P. Angiogenesis in life, disease and medicine. Nature 2005, 42, 932-936.
48. Li, Y.; Cozzi, P. J. Angiogenesis as a strategic target for prostate cancer therapy. Med. Res. Rev. 2009, 30, 23-66.
49. Zucker, S.; Hymowitz, M.; Rollo, E. E.; Mann, R.; Conner, C. E.; Cao, J.; Foda, H. D.; Tompkins, D. C.; Toole, B. P. Tumorigenic Potential of Extracellular Matrix Metalloproteinase Inducer. Am. J. Pathol. 2001, 158, 1921-1928.
50. Tang, Y.; Kesavan, P.; Nakada, M. T.; Yan, L. Tumor-stroma interaction: positive feedback regulation of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase-dependent generation of soluble EMMPRIN. Mol. Cancer Res. 2004, 2, 73-80.
51. Zhang, W.; Erkan, M.; Abiatari, I.; Giese, N. A.; Felix, K.; Kayed, H.; Büchler, M. W.; Friess, H.; Kleeff, J. Expression of extracellular matrix metalloproteinase inducer (EMMPRIN/CD147) in pancreatic neoplasm and pancreatic stellate cells. Cancer Biol. Ther. 2007, 6, 218-227.
52. Zheng, H. C.; Takahashi, H.; Murai, Y.; Cui, Z. G.; Nomoto, K.; Miwa, S.; Tsuneyama, K.; Takano, Y. Upregulated EMMPRIN/CD147 might contribute to growth and angiogenesis of gastric carcinoma: a good marker for local invasion and prognosis. Br. J. Cancer 2006, 95, 1371-1378.
53. Millimaggi, D.; Mari, M.; D'Ascenzo, S.; Carosa, E.; Jannini, E. A.; Zucker, S.; Carta, G.; Pavan, A.; Dolo, V. Tumor vesicleassociated CD147 modulates the angiogenic capability of endothelial cells. Neoplasia 2007, 9, 349-357.
54. Rosenthal, E. L.; Vidrine, D. M.; Zhang, W. Extracellular matrix metalloprotease inducer stimulates fibroblast mediated tumor growth in vivo. Laryngoscope 2006, 116, 1086-1092.
55. Zhang, W.; Matrisian, L. M.; Holmeck, K.; Vick, C. C.; Rosenthal, E. L. Fibroblast-derived MT1-MMP promotes tumor progression in vitro and in vivo. BMC Cancer 2006, 6, 52.
56. Caudroy, S.; Polette, M.; Nawrocki-Raby, B.; Cao, J.; Toole, B. P.; Zucker, S.; Birembaut, P. EMMPRIN-mediated MMP regulation in tumor and endothelial cells.Clin. Exp. Metastasis 2002, 19, 697-702.
57. Braundmeier, A. G.; Fazleabas, A. T.; Lessey, B. A.; Guo, H.; Toole, B. P.; Nowak, R. A. Extracellular matrix metalloproteinase inducer regulates metalloproteinases in human uterine endometrium. J. Clin. Endocrinol. Metab. 2006, 91, 2358-2365.
58. Dalberg, K.; Eriksson, E.; Enberg, U.; Kjellman, M.; Backdahl, M. Gelatinase A, membrane type 1 matrix metalloproteinase, and extracellular matrix metalloproteinase inducer mRNA expression: correlation with invasive growth of breast cancer. World J. Surg. 2000, 24, 334-340.
59. Overall, C. M.; Kleifeld, O. Tumour microenvironment--opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat. Rev. Cancer 2006, 6, 227-239.
60. Yang, J. M.; O'Neill, P.; Jin, W.; Foty, R.; Medina, D. J.; Xu, Z.; Lomas, M.; Arndt, G. M.; Tang, Y.; Nakada, M.; Yan, L.; Hait, W. N. Extracellular matrix metalloproteinase inducer (CD147) confers resistance of breast cancer cells to Anoikis through inhibition of Bim. J. Biol. Chem. 2006, 281, 9719-9727.
61. Li, Q. Q.; Wang, W. J.; Xu, J. D.; Cao, X. X.; Chen, Q.; Yang, J. M.; Xu, Z. D. Involvement of CD147 in regulation of multidrug resistance to P-gp substrate drugs and in vitro invasion in breast cancer cells. Cancer Sci. 2007, 98, 1064-1069.
62. Wang, L.; Wu, G.; Yu, L.; Yuan, J.; Fang, F.; Zhai, Z.; Wang, F.; Wang, H. Inhibition of CD147 expression reduces tumor cell invasion in human prostate cancer cell line via RNA interference. Cancer Biol. Ther. 2006, 5, 608-614.
63. Li, M.; Zhai, Q.; Bharadwaj, U.; Wang, H.; Li, F.; Fisher, W. E.; Chen, C.; Yao, Q. Cyclophilin A is overexpressed in human pancreatic cancer cells and stimulates cell proliferation through CD147. Cancer 2006, 106, 2284-2294.
64. Quemener, C.; Gabison, E. E.; Naimi, B.; Lescaille, G.; Bougatef, F.; Podgorniak, M. P.; Labarchede, G.; Lebbe, C.; Calvo, F.; Menashi, S.; Mourah, S. Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion. Cancer Res. 2007, 67, 9-15.
65. Bordador, L. C.; Li, X.; Toole, B.; Chen, B.; Regezi, J.; Zardi, L.; Hu, Y.; Ramos, D. M. Expression of emmprin by oral squamous cell carcinoma. Int. J. Cancer 2000, 85, 347-352.
66. Rosenthal, E. L.; Shreenivas, S.; Peters, G. E.; Grizzle, W. E.; Desmond, R.; Gladson, C. L. Expression of extracellular matrix metalloprotease inducer in laryngeal squamous cell carcinoma. Laryngoscope 2003, 113, 1406-1410.
67. Sameshima, T.; Nabeshima, K.; Toole, B. P.; Yokogami, K.; Okada, Y.; Goya, T.; Koono, M.; Wakisaka, S. Glioma cell extracellular matrix metalloproteinase inducer (EMMPRIN) (CD147) stimulates production of membrane-type matrix metalloproteinases and activated gelatinase A in co-cultures with brain-derived fibroblasts. Cancer Lett. 2000, 157, 177-184.
68. Kanekura, T.; Chen, X.; Kanzaki, T. Basigin (CD147) is expressed onmelanoma cells and induces tumor cell invasionby stimulating production of matrixmetalloproteinases by fibroblasts. Int. J. Cancer 2002, 99, 520-528.
69. Du, Z. M.; Hu, C. F.; Shao, Q.; Huang, M. Y.; Kou, C. W.; Zhu, X. F.; Zeng, Y. X.; Shao, J. Y. Upregulation of caveolin-1 and CD147 expression in nasopharyngeal carcinoma enhanced tumor cell migration and correlated with poor prognosis of the patients. Int. J. Cancer 2009, 125(8), 1832-1841.
70. Reimers, N.; Zafrakas, K.; Assmann, V.; Egen, C.; Riethdorf, L.; Riethdorf, S.; Berger, J.; Ebel, S.; Jänicke, F.; Sauter, G.; Pantel, K. Expression of extracellular matrix metalloproteases inducer on mi- Hao et al. crometastatic and primary mammary carcinoma cells. Clin. Cancer Res. 2004, 10, 3422-3428.
71. Ju, X. Z.; Yang, J. M.; Zhou, X. Y.; Li, Z. T.; Wu, X. H. EMMPRIN expression as a prognostic factor in radiotherapy of cervical cancer. Clin.Cancer Res. 2008, 14, 494-501.
72. Hanata, K.; Yamaguchi, N.; Yoshikawa, K.; Mezaki, Y.; Miura, M.; Suzuki, S.; Senoo, H.; Ishikawa, K. Soluble EMMPRIN (extracellular matrix metalloproteinase inducer) stimulates the migration of HEp-2 human laryngeal carcinoma cells, accompanied by increased MMP-2 production in fibroblasts. Arch. Histol. Cytol. 2007, 70, 267-277.
73. Ishibashi, Y.; Matsumoto, T.; Niwa, M.; Suzuki, Y.; Omura, N.; Hanyu, N.; Nakada, K.; Yanaga, K.; Yamada, K.; Ohkawa, K.; Kawakami, M.; Urashima, M. CD147 and matrix metalloproteinase-2 protein expression as significant prognostic factors in esophageal squamous cell carcinoma. Cancer 2004, 101, 1994-2000.
74. Sillanpaa, S.; Anttila, M.; Suhonen, K.; Hamalainen, K.; Turpeenniemi-Hujanen, T.; Puistola, U.; Tammi, M.; Sironen, R.; Saarikoski, S.; Kosma, V. M. Prognostic significance of extracellular matrix metalloproteinase inducer and matrix metalloproteinase 2 in epithelial ovarian cancer. Tumour Biol. 2007, 28, 280-289.
75. Als, A. B.; Dyrskjøt, L.; von der Maase, H.; Koed, K.; Mansilla, F.; Toldbod, H. E.; Jensen, J. L.; Ulhøi, B. P.; Sengeløv, L.; Jensen, K. M.; Orntoft, T. F. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin. Cancer Res. 2007, 13, 4407-4414.
76. Tsai, W. C.; Chao, Y. C.; Lee, W. H.; Chen, A.; Sheu, L. F.; Jin, J. S. Increasing EMMPRIN and matriptase expression in hepatocellular carcinoma: tissue microarray analysis of immunohistochemical scores with clinicopathological parameters. Histopathology 2006, 49, 388-395.
77. Kanekura, T.; Chen, X. CD147/basigin promotes progression of malignant melanoma and other cancers. J. Dermatol Sci. 2010, 57, 149-54.
78. Zhong, W. D.; Han, Z. D.; He, H. C.; Bi, X. C.; Dai, Q. S.; Zhu, G.; Ye, Y. K.; Liang, Y. X.; Qin, W. J.; Zhang, Z.; Zeng, G. H.; Chen, Z. N. CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer. Oncology 2008, 75, 230-236.
79. Sienel, W.; Polzer, B.; Elshawi, K.; Lindner, M.; Morresi-Hauf, A.; Vay, C.; Eder, F.; Passlick, B.; Klein, C. A. Cellular localization of EMMPRIN predicts prognosis of patients with operable lung adenocarcinoma independent from MMP-2 and MMP-9. Mod. Pathol. 2008, 21, 1130-1138.
80. Toole, B. P. Hyaluronan: from extracellular glue to pericellular cue. Nat. Rev. Cancer 2004, 4, 528-539.
81. Yang, J. M.; Xu, Z.; Wu, H.; Zhu, H.; Wu, X.; Hait, W. N. Overexpression of Extracellular Matrix Metalloproteinase Inducer in Multidrug Resistant Cancer Cells. Mol. Cancer Res. 2003, 1, 420-427.
82. Zou, W.; Yang, H.; Hou, X.; Zhang, W.; Chen, B.; Xin, X. Inhibition of CD147 gene expression via RNA interference reduces tumor cell invasion,; tumorigenicity and increases chemosensitivity to paclitaxel in HO-8910pm cells. Cancer Lett. 2007, 248, 211-218.
83. Yang, H.; Zou, W.; Li, Y.; Chen, B.; Xin, X. Bridge linkage role played by CD98hc of anti-tumor drug resistance and cancer metastasis on cisplatin-resistant ovarian cancer cells. Cancer Biol. Ther. 2007, 6, 942-947.
84. Kuang, Y. H.; Chen, X.; Su, J.; Wu, L. S.; Li, J.; Chang, J.; Qiu, Y.; Chen, Z. S.; Kanekura, T. Proteome analysis of multidrug resistance of human oral squamous carcinoma cells using CD147 silencing. J. Proteome Res. 2008, 7, 4784-4791.
85. Kuang, Y. H.; Chen, X.; Su, J.; Wu, L. S.; Liao, L. Q.; Li, D.; Chen, Z. S.; Kanekura, T. RNA interference targeting the CD147 induces apoptosis of multi-drug resistant cancer cells related to XIAP depletion. Cancer Lett. 2009, 276, 189-195.
86. Jia, L.; Wei, W.; Cao, J.; Xu, H.; Miao, X.; Zhang, J. Silencing CD147 inhibits tumor progression and increases chemosensitivity in murine lymphoid neoplasm P388D1 cells. Ann. Hematol. 2009, 88, 753-760.
87. Semenza, G. L.; Roth, P. H.; Fang, H. M.; Wang, G. L. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxiainducible factor 1. J. Biol. Chem. 1994, 269, 23757-23763.
88. Gatenby, R. A.; Gillies, R. J. Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer 2004, 4, 891-899.
89. Schlappack, O. K.; Zimmermann, A.; Hill, R. P. Glucose starvation and acidosis: effect on experimental metastatic potential, DNA content and MTX resistance of murine tumour cells. Br. J. Cancer 1991, 64, 663-670.
90. Bennett, D. C.; Holmes, A.; Devlin, L.; Hart, I. R. Experimental metastasis and differentiation of murine melanoma cells: actions and interactions of factors affecting different intracellular signaling pathways. Clin. Exp. Metastatis 1994, 12, 385-397.
91. Rozhin, J.; Sameni, M.; Ziegler, G.; Sloane, B. F. Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Res. 1994, 54, 6517-6525.
92. Martinez-Zaguilan, R.; Seftor, E. A.; Seftor, R. E.; Chu, Y. W., Gillies, R. J.; Hendrix, M. J. Acidic pH enhances the invasive behavior of human melanoma cells. Clin. Exp. Metastasis 1996, 14, 176-186.
93. Cuvier, C.; Jang, A.; Hill, R. P. Exposure to hypoxia, glucose starvation and acidosis: Effect on the invasive capacity of murine tumor cells and correlation with cathepsin (L+B). Clin. Exp. Metastatis. 1997, 15, 19-25.
94. Gatenby, R. A.; Gawlinski, E. T.; Gmitro, A. F.; Kaylor, B.; Gillies, R. J. Acidmediated tumor invasion: A multidisciplinary study. Cancer Res. 2006, 66, 5216-5223.
95. Rofstad, E. K.; Mathiesen, B.; Kindem, K.; Galappathi, K. Acidic extracellular pH promotes experimental metastasis of human melanoma cells in athymic nude mice. Cancer Res. 2006, 66, 6699-6707.
96. Koukourakis, M. I.; Giatromanolaki, A.; Harris, A. L.; Sivridis, E. Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. Cancer Res. 2006, 66, 632-627.
97. Pelicano, H.; Martin, D. S.; Xu, R. H.; Huang, P. Glycolysis inhibition for anticancer treatment. Oncogene 2006, 25, 4633-4646.
98. Tredan, O.; Galmarini, C. M.; Patel, K.; Tannock, I. F. Drug resistance and the solid tumor microenvironment. J. Natl. Cancer Inst. 2007, 99, 1441-1454.
99. Albers, M. J.; Bok R.; Chen, A. P.; Cunningham, C. H.; Zierhut, M. L.; Zhang, V. Y.; Kohler, S. J.; Tropp, J.; Hurd, R. E.; Yen, Y. F.; Nelson, S. J.; Vigneron, D. B.; Kurhanewicz, J. Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. Cancer Res. 2008, 68, 8607-8615.
100. Gatenby, R. A.; Gillies, R. J. Glycolysis in cancer: a potential target for therapy. Int. J. Biochem. Cell Biol. 2007, 39, 1358-1366.
101. Enerson, B. E.; Drewes, L. R. Molecular features, regulation, and function of monocarboxylate transporters: implications for drug delivery. J. Pharm. Sci. 2003, 92, 1531-1544.
102. Deora, A. A.; Philp, N.; Hu, J.; Bok, D.; Rodriguez-Boulan, E. Mechanisms regulating tissue-specific polarity of monocarboxylate transporters and their chaperone CD147 in kidney and retinal epithelia. Proc. Natl. Acad. Sci. USA 2005, 102, 16245-16250.
103. Wilson, M. C.; Meredith, D.; Halestrap, A. P. Fluorescence resonance energy transfer studies on the interaction between the lactate transporter MCT1 and CD147 provide information on the topology and stoichiometry of the complex in situ. J. Biol. Chem. 2002, 277, 3666-3672.
104. Wilson, M. C.; Meredith, D.; Fox, J. E.; Manoharan, C.; Davies, A. J.; Halestrap, A. P. Basigin (CD147) is the target for organomercurial inhibition of monocarboxylate transporter isoforms 1 and 4: the ancillary protein for the insensitive MCT2 is EMBIGIN (gp70). J. Biol. Chem. 2005, 280, 27213-27221.
105. Gallagher, S. M.; Castorino, J. J.; Wang, D.; Philp, N. J. Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231. Cancer Res. 2007, 67, 4182-4189.
106. Fang, J.; Quinones, Q. J.; Holman, T. L.; Morowitz, M. J.; Wang, Q.; Zhao, H.; Sivo, F.; Maris, J. M.; Wahl, M. L. The H+-linked monocarboxylate transporter (MCT1/SLC16A1): a potential therapeutic target for high-risk neuroblastoma. Mol. Pharmacol. 2006, 70, 2108-2115.
107. Froberg, M. K.; Gerhart, D. Z.; Enerson, B. E.; Manivel, C.; Guzman-Paz, M.; Seacotte, N.; Drewes, L. R. Expression of monocarboxylate transporter MCT1 in normal and neoplastic human CNS tissues. Neuroreport 2001, 12, 761-765.
108. Slomiany, M. G.; Grass, G. D.; Robertson, A. D.; Yang, X. Y.; Maria, B. L.; Beeson, C.; Toole, B. P. Hyaluronan, CD44, and emmprin regulate lactate efflux and membrane localization of monocarboxylate transporters in human breast carcinoma cells. Cancer Res. 2009, 69, 1293-1301.
109. Schneiderhan, W.; Scheler, M.; Holzmann, K. H.; Marx, M.; Gschwend, J. E.; Bucholz, M.; Gress, T. M.; Seufferlein, T.; Adler, G.; Oswald, F. CD147 silencing inhibits lactate transport and reduces malignant potential of pancreatic cancer cells in in-vivo and in-vitro models. Gut 2009, 58, 1391-1398.
110. Su, J.; Chen, X.; Kanekura, T. A CD147-targeting siRNA inhibits the proliferation,; invasiveness,; and VEGF production of human malignant melanoma cells by down-regulating glycolysis. Cancer Lett. 2009, 273, 140-147.
111. Baba, M.; Inoue, M.; Itoh, K.; Nishizawa, Y. Blocking CD147 induces cell death in cancer cells through impairment of glycolytic energy metabolism. Biochem. Biophys. Res. Commun. 2008, 374, 111-116.
112. Mamori, S.; Nagatsuma, K.; Matsuura, T.; Ohkawa, K.; Hano, H.; Fukunaga, M.; Matsushima, M.; Masui, Y.; Fushiya, N.; Onoda, H.; Searashi, Y.; Takagi, I.; Tagiri, H. Useful detection of CD147 (EMMPRIN) for pathological diagnosis of early hepatocellular carcinoma in needle biopsy samples. World J. Gastroenterol. 2007, 13, 2913-2917.
113. Newman, J. R.; Gleysteen, J. P.; Baranano, C. F.; Bremser, J. R.; Zhang, W.; Zinn, K. R.; Rosenthal, E. L. Stereomicroscopic fluorescence imaging of head and neck cancer xenografts targeting CD147. Cancer Biol. Ther. 2008, 7, 1063-1070.
114. Klein, C. A.; Seidl, S.; Petat-Dutter, K.; Offner, S.; Geigl, J. B.; Schmidt-Kittler, O.; Wendler, N.; Passlick, B.; Huber, R. M.; Schlimok, G.; Baeuerle, P. A.; Riethmüller, G. Combined transcriptome and genome analysis of single micrometastatic cells. Nat. Biotechnol. 2002, 20, 387-392.
115. Liu, A. Y.; LaTray, L.; van Den Engh, G. Changes in cell surface molecules associated with in vitro culture of prostatic stromal cells. Prostate 2000, 44, 303-312.
116. Riethdorf, S.; Reimers, N.; Assmann, V.; Kornfeld, J. W.; Terracciano, L.; Sauter, G.; Pantel, K. High Incidence of EMMPRIN Expression in Human Tumors. Int. J. Cancer 2006, 119, 1800-1810.
117. Han, Z. D.; Bi, X. C.; Qin, W. J.; He, H. C.; Dai, Q. S.; Zou, J.; Ye, Y. K.; Liang, Y. X.; Zeng, G. H.; Chen, Z. N.; Zhong, W. D. CD147 Expression Indicates Unfavourable Prognosis in Prostate Cancer. Pathol. Oncol. Res. 2008, 15, 369-374.
118. Xu, J.; Xu, H. Y.; Zhang, Q.; Song, F.; Jiang, J. L.; Yang, X. M.; Mi, L.; Wen, N.; Tian, R.; Wang, L.; Yao, H.; Feng, Q.; Zhang, Y.; Xing, J. L.; Zhu, P.; Chen, Z. N. HAb18G/CD147 functions in invasion and metastasis of hepatocellular carcinoma. Mol. Cancer Res. 2007, 5, 605-614
119. Dean, N. R.; Newman, J. R.; Helman, E. E.; Zhang, W.; Safavy, S.; Weeks, D. M.; Cunningham, M.; Snyder, L. A.; Tang, Y.; Yan, L.; McNally, L. R.; Buchsbaum, D. J.; Rosenthal, E. L. Anti- EMMPRIN monoclonal antibody as a novel agent for therapy of head and neck cancer. Clin. Cancer Res. 2009, 15, 4058-4065.
120. Deeg, H. J.; Blazar, B. R.; Bolwell, B. J., Long, G. D.; Schuening, F.; Cunningham, J.; Rifkin, R. M.; Abhyankar, S.; Briggs, A. D.; Burt, R.; Lipani, J.; Roskos, L. K.; White, J. M.; Havrilla, N.; Schwab, G.; Heslop, H. E. Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. Blood 2001, 98, 2052-2058.
121. Macmillan, M. L.; Couriel, D.; Weisdorf, D. J.; Schwab, G.; Havrilla, N.; Fleming, T. R.; Huang, S.; Roskos, L.; Slavin, S.; Shadduck, R. K.; Dipersio, J.; Territo, M.; Pavletic, S.; Linker, C.; Heslop, H. E.; Joachim Deeg, H.; Blazar, B. R. A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood 2007, 109, 2657-2662.
122. Chen, Z. N.; Mi, L.; Xu, J.; Song, F.; Zhang, Q.; Zhang, Z.; Xing, J. L.; Bian, H. J.; Jiang, J. L.; Wang, X. H.; Shang, P.; Qian, A. R.; Zhang, S. H.; Li, L.; Li, Y.; Feng, Q.; Yu, X. L.; Feng, Y.; Yang, X. M.; Tian, R.; Wu, Z. B.; Leng, N.; Mo, T. S.; Kuang, A. R.; Tan, T. Z.; Li, Y. C.; Liang, D. R.; Lu, W. S.; Miao, J.; Xu, G. H.; Zhang, Z. H.; Nan, K. J.; Han, J.; Liu, Q. G.; Zhang, H. X.; Zhu, P. Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials. Int. J. Radiat. Oncol. Biol. Phys. 2006, 65, 435-444.
123. Xu, J.; Shen, Z. Y.; Chen, X. G.; Zhang, Q.; Bian, H. J.; Zhu, P.; Xu, H. Y.; Song, F.; Yang, X. M.; Mi, L.; Zhao, Q. C.; Tian, R.; Feng, Q.; Zhang, S. H.; Li, Y.; Jiang, J. L.; Li, L.; Yu, X. L.; Zhang, Z.; Chen, Z. N. A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology 2007, 45, 269-276.
124. Haynes, B. F.; Telen, M. J.; Hale, L. P.; Denning, S. M. CD44--a molecule involved in leukocyte adherence and T-cell activation. Immunol. Today 1989, 10, 423-428.
125. Underhill, C. CD44: the hyaluronan receptor. J. Cell Sci. 1992, 103, 293-298.
126. Naor, D.; Sionov, R. V.; Ish-Shalom, D. CD44: structure, function, and association with the malignant process. Adv. Cancer Res. 1997, 58, 241-319.
127. Ponta, H.; Sherman, L.; Herrlich, P. A. CD44: from adhesion molecules to signalling regulators. Nat. Rev. Mol. Cell Biol. 2003, 4, 33-45.
128. Okamoto, I.; Morisaki, T.; Sasaki, J.; Miyake, H.; Matsumoto, M.; Suga, M.; Ando, M.; Saya, H. Molecular detection of cancer cells by competitive reverse transcription-polymerase chain reaction analysis of specific CD44 variant RNAs. J. Natl. Cancer Inst. 1998, 90, 307-315.
129. Iwase, A.; Shen, R.; Navarro, D.; Nanus, D. M. Direct binding of neutral endopeptidase 24.11 to ezrin/radixin/moesin (ERM) proteins competes with the interaction of CD44 with ERM proteins. J. Biol. Chem. 2004, 279, 11898-11905.
130. Screaton, G. R.; Bell, M. V.; Jackson, D. G.; Cornelis, F. B.; Gerth, U.; Bell, J. I. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc. Natl. Acad. Sci. USA 1992, 89, 12160-12164.
131. Takahashi, K.; Stamenkovic, I.; Cutler, M.; Dasgupta, A.; Tanabe, K. K. Keratan sulfate modification of CD44 modulates adhesion to hyaluronate. J. Biol. Chem. 1996, 271, 9490-9496.
132. Liu, J.; Jiang, G. CD44 and hematologic malignancies. Cell Mol. Immunol. 2006, 3, 359-365.
133. Miyoshi, T.; Kondo, K.; Hino, N.; Uyama, T.; Monden, Y. The expression of the CD44 variant exon 6 is associated with lymph node metastasis in non-small cell lung cancer. Clin. Cancer Res. 1997, 3, 1289-1297.
134. Yamaguchi, A.; Goi, T.; Taguchi, S.; Ohtaki, N.; Seki, K.; Hirose, K.; Nakagawara, G.; Urano, T.; Furukawa, K. Clinical significance of serum levels of CD44 variant exons 8-10 protein in colorectal cancer. J. Gastroenterol. 1998, 33, 349-353.
135. Kinoshita, J.; Haga, S.; Shimizu, T.; Imamura, H.; Watanabe, O.; Kajiwara, T. The expression of variant exon v7-v8 CD44 antigen in relation to lymphatic metastasis of human breast cancer. Breast Cancer Res. Treat. 1999, 53, 177-183.
136. Abraham, B. K.; Fritz, P.; McClellan, M.; Hauptvogel, P.; Athelogou, M.; Brauch, H. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin. Cancer Res. 2005, 11, 1154-1159.
137. Draffin, J. E.; McFarlane, S.; Hill, A.; Johnston, P. G.; Waugh, D. J. CD44 potentiates the adherence of metastatic prostate and breast cancer cells to bone marrow endothelial cells. Cancer Res. 2004, 64, 5702-5711.
138. Klingbeil, P.; Marhaba, R.; Jung, T.; Kirmse, R.; Ludwig, T.; Zoller, M. CD44 variant isoforms promote metastasis formation by a tumor cell-matrix cross-talk that supports adhesion and apoptosis resistance. Mol. Cancer Res. 2009, 7, 168-179.
139. Golshani, R.; Lopez, L.; Estrella, V.; Kramer, M.; Iida, N.; Lokeshwar, V. B. Hyaluronic acid synthase-1 expression regulates bladder cancer growth, invasion, and angiogenesis through CD44. Cancer Res. 2008, 68, 483-491.
140. Ouhtit, A.; Abd Elmageed, Z. Y.; Abdraboh, M. E.; Lioe, T. F.; Raj, M. H. In vivo evidence for the role of CD44s in promoting breast cancer metastasis to the liver. Am. J. Pathol. 2007, 171, 2033-2039.
141. Desai, B.; Rogers, M. J.; Chellaiah, M. A. Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells. Mol. Cancer 2007, 6, 18.
142. Sheridan, C.; Kishimoto, H.; Fuchs, R. K.; Mehrotra, S.; Bhat- Nakshatri, P.; Turner, C. H.; Goulet, R. Jr.; Badve, S.; Nakshatri, H. CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res. 2006, 8, R59.
143. Kim, H. R.; Wheeler, M. A.; Wilson, C. M.; Iida, J.; Eng, D.; Simpson, M. A.; McCarthy, J. B.; Bullard, K. M. Hyaluronan facilitates invasion of colon carcinoma cells in vitro via interaction with CD44. Cancer Res. 2004, 64, 4569-4576.
144. Harrison, G. M.; Davies, G.; Martin, T. A.; Jiang, W. G.; Mason, M. D. Distribution and expression of CD44 isoforms and Ezrin during prostate cancer-endothelium interaction. Int. J. Oncol. 2002, 21, 935-940.
145. Weber, G. F.; Bronson, R. T.; Ilagan, J.; Cantor, H.; Schmits, R.; Mak, T. W. Absence of the CD44 gene prevents sarcoma metastasis. Cancer Res. 2002, 62, 2281-2286.
146. Kuniyasu, H.; Oue, N.; Tsutsumi, M.; Tahara, E.; Yasui, W. Heparan sulfate enhances invasion by human colon carcinoma cell lines through expression of CD44 variant exon 3. Clin. Cancer Res. 2001, 7, 4067-4072.
147. Cordo Russo, R. I.; García, M. G.; Alaniz, L.; Blanco, G.; Alvarez, E.; Hajos, S. E. Hyaluronan oligosaccharides sensitize lymphoma resistant cell lines to vincristine by modulating P-glycoprotein activity and PI3K/Akt pathway. Int. J. Cancer 2008, 122, 1012-1018.
148. Misra, S.; Ghatak, S.; Toole, B. P. Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. J. Biol. Chem. 2005, 280, 20310-20315.
149. Bourguignon, L. Y.; Peyrollier, K.; Xia, W.; Gilad, E. Hyaluronan- CD44 interaction activates stem cell marker Nanog, Stat-3- mediated MDR1 gene expression,; and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J. Biol. Chem. 2008, 283, 17635-17651.
150. Takaishi, S.; Okumura, T.; Tu, S.; Wang, S. S.; Shibata, W.; Vigneshwaran, R.; Gordon, S. A.; Shimada, Y.; Wang, T. C. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 2009, 27, 1006-1020.
151. Liu, C. M.; Chang, C. H.; Yu, C. H.; Hsu, C. C.; Huang, L. L. Hyaluronan substratum induces multidrug resistance in human mesenchymal stem cells via CD44 signaling. Cell Tissue Res. 2009, 336, 465-475.
152. Xie, Z.; Choong, P. F.; Poon, L. F.; Zhou, J.; Khng, J.; Jasinghe, V. J.; Palaniyandi, S.; Chen, C. S. Inhibition of CD44 expression in hepatocellular carcinoma cells enhances apoptosis, chemosensitivity, and reduces tumorigenesis and invasion. Cancer Chemother. Pharmacol. 2008, 62, 949-957.
153. Colone, M.; Calcabrini, A.; Toccacieli, L.; Bozzuto, G.; Stringaro, A.; Gentile, M.; Cianfriglia, M.; Ciervo, A.; Caraglia, M.; Budillon, A.; Meo, G.; Arancia, G.; Molinari, A. The multidrug transporter P-glycoprotein: a mediator of melanoma invasion? J. Invest. Dermatol. 2008, 128, 957-971.
154. Lakshman, M.; Subramaniam, V.; Rubenthiran, U.; Jothy, S. CD44 promotes resistance to apoptosis in human colon cancer cells. Exp. Mol. Pathol. 2004, 77, 18-25.
155. Chen, H.; Hao, J.; Wang, L.; Li, Y. Coexpression of invasive markers (uPA,; CD44) and multiple drug resistance proteins (MDR1,; MRP2) is correlated with epithelial ovarian cancer progression. Br. J. Cancer 2009, 101, 432-440.
156. Nagabhushan, M.; Pretlow, T. G.; Guo, Y. J.; Amini, S. B.; Pretlow, T. P.; Sy, M. S. Altered expression of CD44 human prostate cancer during progression. Am. J. Clin. Pathol. 1996, 106, 647-651.
157. Noordzij, M. A.; van Steenbrugge, G. J.; Verkaik, N. S.; Schroder, F. H.; van der Kwast, T. H. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy. Clin. Cancer Res. 1997, 3, 805-815.
158. De Marzo, A. M.; Bradshaw, C.; Sauvageot, J.; Epstein, J. I.; Miller, G. J. CD44 and CD44v6 downregulation in clinical prostatic carcinoma: relation to Gleason grade and cytoarchitecture. Prostate 1998, 34, 162-168.
159. Noordzij, M. A.; van Steenbrugge, G. J.; Schroder, F. H.; Van der Kwast, T. H. Decreased expression of CD44 in metastatic prostate cancer. Int. J. Cancer 1999, 84, 478-483.
160. Alam, T. N.; O'Hare, M. J.; Laczkó, I.; Freeman, A.; Al-Beidh, F.; Masters, J. R.; Hudson, D. L. Differential expression of CD44 dur- CD147 and CD44 in Prostate Cancer ing human prostate epithelial cell differentiation. J. Histochem. Cytochem. 2004, 52, 1083-1090.
161. Kallakury, B. V.; Yang, F.; Figge, J.; Smith, K. E.; Kausik, S. J.; Tacy, N. J.; Fisher, H. A.; Kaufman, R.; Figge, H.; Ross, J. S. Cancer 1996, 78, 1461-1469.
162. Paradis, V.; Eschwege, P.; Loric, S.; Dumas, F.; Ba, N.; Benoit, G.; Jardin, A.; Bedossa, P. De Novo Expression of CD44 in Prostate Carcinoma Is Correlated with Systemic Dissemination of Prostate Cancer. J. Clin. Pathol. 1998, 51, 798-802.
163. Liu, A. Y.; True, L. D.; LaTray, L.; Ellis, W. J.; Vessella, R. L.; Lange, P. H.; Higano, C. S.; Hood, L.; van den Engh, G. Prostate 1999, 40, 192-199.
164. Gao, A. C.; Lou, W.; Dong, J. T.; Isaacs, J. T. CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res. 1997, 57, 846-849.
165. Lokeshwar, B. L.; Lokeshwar, V. B.; Block, N. L. Anticancer Res. 1995, 15, 1191-1198.
166. Harrison, G. M.; Davies, G.; Martin, T. A.; Mason, M. D.; Jiang, W. G. The influence of CD44v3-v10 on adhesion, invasion and MMP-14 expression in prostate cancer cells. Oncol. Rep. 2006, 15, 199-206.
167. Takahashi, S.; Kimoto, N.; Orita, S.; Cui, L.; Sakakibara, M.; Shirai, T. Relationship between CD44 expression and differentiation of human prostate adenocarcinomas. Cancer Lett. 1998, 129, 97-102.
168. Lipponen, P.; Aaltomaa, S.; Tammi, R.; Tammi, M.; Agren, U.; Kosma, V. M. High stromal hyaluronan level is associated with poor differentiation and metastasis in prostate cancer. Eur. J. Cancer 2001, 37, 849-856.
169. Peehl, D. M.; Coram, M.; Khine, H.; Reese, S.; Nolley, R.; Zhao, H. The significance of monoamine oxidase-A expression in high grade prostate cancer. J. Urol. 2008, 180, 2206-2211.
170. Simon, R. A.; di Sant'Agnese, P. A.; Huang, L. S.; Xu, H.; Yao, J. L.; Yang, Q.; Liang, S.; Liu, J.; Yu, R.; Cheng, L.; Oh, W. K.; Palapattu, G. S.; Wei, J.; Huang, J. CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers. Hum. Pathol. 2009, 40, 252-258.
171. Dalerba, P.; Dylla, S. J.; Park, I. K.; Liu, R.; Wang, X.; Cho, R. W.; Hoey, T.; Gurney, A; Huang, E. H.; Simeone, D. M.; Shelton, A. A.; Parmiani, G.; Castelli, C.; Clarke, M. F. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. Acad. Sci. USA 2007, 104, 10158-10163.
172. Rizzo, S.; Attard, G.; Hudson, D. L. Prostate epithelial stem cells. Cell Prolif. 2005, 38, 363-374.
173. Litvinov, I. V.; De Marzo, A. M.; Isaacs, J. T. Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J. Clin. Endocrinol. Metab. 2003, 88, 2972-2982.
174. Wang, S.; Gao, J.; Lei, Q.; Rozengurt, N.; Pritchard, C.; Jiao, J.; Thomas, G. V.; Li, G.; Roy-Burman, P.; Nelson, P. S.; Liu, X.; Wu, H. Prostate specific deletion of the murine PTEN tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003, 4, 209-221.
175. Signoretti, S.; Pires, M. M.; Lindauer, M.; Horner, J. W.; Grisanzio, C.; Dhar, S.; Majumder, P.; McKeon, F.; Kantoff, P. W.; Sellers, W. R.; Loda, M. p63 regulates commitment to the prostate cell lineage. Proc. Natl. Acad. Sci. USA 2005, 102, 11355-11360.
176. Patrawala, L.; Calhoun, T.; Schneider-Broussard, R.; Li, H.; Bhatia, B.; Tang, S.; Reilly, J. G.; Chandra, D.; Zhou, J.; Claypool, K.; Coghlan, L.; Tang, D. G. Highly Purified CD44+ Prostate Cancer Cells from Xenograft Human Tumors Are Enriched in Tumorigenic and Metastatic Progenitor Cells. Oncogene 2006, 25, 1696-1708.
177. Hurt, E. M.; Kawasaki, B. T.; Klarmann, G. J.; Thomas, S. B.; Farrar, W. L. CD44(+)CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br. J. Cancer 2008, 98, 756-765.
178. Yang, M.; Jiang, P.; Sun, F. X.; Hasegawa, S.; Baranov, E.; Chishima, T.; Shimada, H.; Moossa, A. R.; Hoffman, R. M. A fluorescent orthotopic bone metastasis model of human prostate cancer. Cancer Res. 1999, 59, 781-786.
179. van Bokhoven, A.; Varella-Garcia, M.; Korch, C.; Johannes, W. U.; Smith, E. E.; Miller, H. L.; Nordeen, S. K.; Miller, G. J.; Lucia, M. S. Molecular characterization of human prostate carcinoma cell lines. Prostate 2003, 57, 205-225.
180. Tang, D. G.; Patrawala, L.; Calhoun, T.; Bhatia, B.; Choy, G.; Schneider-Broussard, R.; Jeter, C. Prostate cancer stem/progenitor cells: identification, characterization, and implications. Mol. Carcinog. 2007, 46, 1-14.
181. Patrawala, L.; Calhoun-Davis, T.; Schneider-Broussard, R.; Tang, D. G. Hierarchical Organization of Prostate Cancer Cells in Xenograft Tumors: The CD44+Alpha2beta1+ Cell Population Is Enriched in Tumor-Initiating Cells. Cancer Res. 2007, 67, 6796-6805.
182. Wei, C.; Guomin, W.; Yujun, L.; Ruizhe, Q. Cancer stem-like cells in human prostate carcinoma cells DU145: the seeds of the cell line. Cancer Biol. Ther. 2007, 6, 763-768.
183. Brown, M. D.; Gilmore, P. E.; Hart, C. A.; Samuel, J. D.; Ramani, V. A.; George, N. J.; Clarke, N. W. Characterization of benign and malignant prostate epithelial Hoechst 33342 side populations. Prostate 2007, 67, 1384-1396.
184. Collins, A. T.; Berry, P. A.; Hyde, C.; Stower, M. J.; Maitland, N. J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005, 65, 10946-10951.
185. Dubrovska, A.; Kim, S.; Salamone, R. J.; Walker, J. R.; Maira, S. M.; Garcia-Echeverria, C.; Schultz, P. G.; Reddy, V. A. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc. Natl. Acad. Sci. USA 2009, 106, 268-273.
186. Bisson, I.; Prowse, D. M. WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res. 2009, 19, 683-697.
187. Rowehl, R. A.; Crawford, H.; Dufour, A.; Ju, J.; Botchkina, G. I. Genomic analysis of prostate cancer stem cells isolated from a highly metastatic cell line. Cancer Genomics Proteomics 2008, 5, 301-310.
188. Palapattu, G. S.; Wu, C.; Silvers, C. R.; Martin, H. B.; Williams, K.; Salamone, L.; Bushnell, T.; Huang, L. S.; Yang, Q.; Huang, J. Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer. Prostate 2009, 69, 787-798.
189. Klarmann, G. J.; Hurt, E. M.; Mathews, L. A.; Zhang, X.; Duhagon, M. A.; Mistree, T.; Thomas, S. B.; Farrar, W. L. Invasive prostate cancer cells are tumor initiating cells that have a stem celllike genomic signature. Clin. Exp. Metastasis 2009, 26, 433-446.
190. Collins, A. T.; Maitland, N. J. Prostate cancer stem cells. Eur. J. Cancer 2006, 42, 1213-1218.
191. Marangoni, E.; Lecomte, N.; Durand, L.; de Pinieux, G.; Decaudin, D.; Chomienne, C.; Smadja-Joffe, F.; Poupon, M. F. CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts. Br. J. Cancer 2009, 100, 918-922.
192. Subramaniam, V.; Vincent, I. R.; Gilakjan, M.; Jothy, S. Suppression of human colon cancer tumors in nude mice by siRNA CD44 gene therapy. Exp. Mol. Pathol. 2007, 83, 332-340.
193. Vercruysse, K. P.; Prestwich, G. D. Hyaluronate derivatives in drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 1998, 15, 513-555.
194. Jaracz, S.; Chen, J.; Kuznetsova, L. V.; Ojima, I. Recent advances in tumor-targeting anticancer drug conjugates. Bioorg. Med. Chem. 2005, 13, 5043-5054.
195. Liao, Y. H.; Jones, S. A.; Forbes, B.; Martin, G. P.; Brown, M. B. Hyaluronan: pharmaceutical characterization and drug delivery. Drug Deliv. 2005, 12, 327-342.
196. Yadav, A. K.; Mishra, P.; Agrawal, G. P. An insight on hyaluronic acid in drug targeting and drug delivery. J. Drug Targeting 2008, 16, 91-107.
197. Platt, V. M.; Szoka, F. C., Jr. Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol. Pharmaceut. 2008, 5, 474-486.
198. Luo, Y.; Ziebell, M. R.; Prestwich, G. D. A hyaluronic acid-taxol antitumor bioconjugate targeted to cancer cells. Biomacromolecules 2000, 1, 208-218.
199. Thankamony, S. P.; Knudson, W. Acylation of CD44 and its association with lipid rafts are required for receptor and hyaluronan endocytosis. J. Biol. Chem. 2006, 281, 34601-34609.
200. Shuster, S.; Frost, G. I.; Csoka, A. B.; Formby, B.; Stern, R. Hyaluronidase reduces human breast cancer xenografts in SCID mice. Int. J. Cancer 2002, 102, 192-197.
201. Rosato, A.; Banzato, A.; De Luca, G.; Renier, D.; Bettella, F.; Pagano, C.; Esposito, G.; Zanovello, P.; Bassi, P. HYTAD1-p20: a new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer. Urol. Oncol. 2006, 24, 207-215.
202. Auzenne, E.; Ghosh, S. C.; Khodadadian, M.; Rivera, B.; Farquhar, D.; Price, R. E.; Ravoori, M.; Kundra, V.; Freedman, R. S.; Klostergaard, J. Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts. Neoplasia 2007, 9, 479-486.
203. Banzato, A.; Bobisse, S.; Rondina, M.; Renier, D.; Bettella, F.; Esposito, G.; Quintieri, L.; Melendez-Alafort, L.; Mazzi, U.; Zanovello, P.; Rosato, A. A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity. Clin. Cancer Res. 2008, 14, 3598-3606.
204. Taetz, S.; Bochot, A.; Surace, C.; Arpicco, S.; Renoir, J. M.; Schaefer, U. F.; Marsaud, V.; Kerdine-Roemer, S.; Lehr, C. M.; Fattal, E. Hyaluronic acid-modified DOTAP/DOPE liposomes for the targeted delivery of anti-telomerase siRNA to CD44-expressing lung cancer cells. Oligonucleotides 2009, 19, 103-116.
205. Surace, C.; Arpicco, S.; Dufaÿ-Wojcicki, A.; Marsaud, V.; Bouclier, C.; Clay, D.; Cattel, L.; Renoir, J. M.; Fattal, E. Lipoplexes targeting the CD44 hyaluronic acid receptor for efficient transfection of breast cancer cell. Mol. Pharm. 2009, 6, 1062-1037.
206. Rosenthal, M. A.; Gibbs, P.; Brown, T. J.; Wong, S.; Uren, S.; Ellis, A.; Li, L.; Heldin, P.; Poliviou, H.; Fox, R. M. Phase I and pharmacokinetic evaluation of intravenous hyaluronic acid in combination with doxorubicin or 5-fluorouracil. Chemotherapy 2005, 51, 132-141.
207. Gibbs, P.; Brown, T. J.; Ng, R.; Jennens, R.; Cinc, E.; Pho, M.; Michael, M.; Fox, R. M. A pilot human evaluation of a formulation of irinotecan and hyaluronic acid in 5-fluorouracil-refractory metastatic colorectal cancer patients. Chemotherapy 2009, 55, 49-59.
208. Naor, D.; Nedvetzki, S.; Golan, I.; Melnik, L.; Faitelson, Y. CD44 in cancer. Crit. Rev. Clin. Lab. Sci. 2002, 39, 527-579.
209. Mackay, C. R.; Terpe, H. J.; Stauder, R.; Marston, W. L.; Stark, H.; Gunthert, U. Expression and modulation of CD44 variant isoforms in humans. J. Cell Biol. 1994, 124, 71-82.
210. Rupp, U.; Schoendorf-Holland, E.; Eichbaum, M.; Schuetz, F.; Lauschner, I.; Schmidt, P.; Staab, A.; Hanft, G.; Huober, J.; Sinn, H. P.; Sohn, C.; Schneeweiss, A. Safety and Pharmacokinetics of Bivatuzumab Mertansine in Patients with CD44v6-Positive Metastatic Breast Cancer: Final Results of a Phase I Study. Anticancer Drugs 2007, 18, 477-485.
211. Koppe, M.; Schaijk, F.; Roos, J.; Leeuwen, P.; Heider, K. H.; Kuthan, H.; Bleichrodt, R. Safety, Pharmacokinetics, Immunogenicity, and Biodistribution of (186)Re-Labeled Humanized Monoclonal Antibody Biwa 4 (Bivatuzumab) in Patients with Early-Stage Breast Cancer. Cancer Biother. Radiopharm. 2004, 19, 720-729.
212. Borjesson, P. K.; Postema, E. J.; Roos, J. C.; Colnot, D. R.; Marres, H. A.; van Schie, M. H.; Stehle, G.; de Bree, R.; Snow, G. B.; Oyen, W. J.; van Dongen, G. A. Phase I Therapy Study with (186)Re-Labeled Humanized Monoclonal Antibody Biwa 4 (Bivatuzumab) in Patients with Head and Neck Squamous Cell Carcinoma. Clin. Cancer Res. 2003, 9, 3961S-3972S.
213. Postema, E. J.; Borjesson, P. K.; Buijs, W. C.; Roos, J. C.; Marres, H. A.; Boerman, O. C.; de Bree, R.; Lang, M.; Munzert, G.; van Dongen, G. A.; Oyen, W. J. Dosimetric Analysis of Radioimmunotherapy with 186re-Labeled Bivatuzumab in Patients with Head and Neck Cancer. J. Nucl. Med. 2003, 44, 1690-1699.
214. Tijink, B. M.; Buter, J.; de Bree, R.; Giaccone, G.; Lang, M. S.; Staab, A.; Leemans, C. R.; van Dongen, G. A. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin. Cancer Res. 2006, 12, 6064-6072.
215. Sauter, A.; Kloft, C.; Gronau, S.; Bogeschdorfer, F.; Erhardt, T.; Golze, W.; Schroen, C.; Staab, A.; Riechelmann, H.; Hoermann, K. Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck. Int. J. Oncol. 2007, 30, 927-935.
216. Colnot, D. R.; Quak, J. J.; Roos, J. C.; van Lingen, A.; Wilhelm, A. J.; van Kamp, G. J.; Huijgens, P. C.; Snow, G. B.; van Dongen, G. A. Phase I Therapy Study of 186re-Labeled Chimeric Monoclonal Antibody U36 in Patients with Squamous Cell Carcinoma of the Head and Neck. J. Nucl. Med. 2000, 41, 1999-2010.